2024-513032-14-00招募中2 期
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Adaptimmune LLC, Adaptimmune LLC8 个研究点 分布在 4 个国家目标入组 21 人开始时间: 2024年6月17日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 21
- 试验地点
- 8
- 主要终点
- Overall Response Rate (ORR) per RECIST v1.1
研究概览
简要总结
To evaluate the efficacy of NY ESO 1 specific (c259) T cells, alone or in combination with other anti-cancer agents, in HLA-A02:01, HLA A02:05 and/or HLA A*02:06 participants with NY ESO 1 and/or LAGE-1a positive solid tumors
入排标准
- 年龄范围
- 0 years 至 65+ years（65+ Years, 0-17 Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •For participants <18 years of age, (or the legal minimum age in the relevant country) their legal guardian must give informed consent. Pediatric subjects will be included in age-appropriate discussion in order to obtain assent.
- •9.Participant is either currently being treated with or has completed at least one standard-of-care treatment including anthracycline-containing regimens (e.g., doxorubicin alone, doxorubicin with ifosfamide) for advanced disease. Participants who are intolerant to anthracycline may receive ifosfamide alone unless intolerant to or ineligible to receive ifosfamide. Participants who received anthracycline-based therapy in the neoadjuvant/adjuvant setting and progressed will be eligible.
- •10.Participant must be positive for HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06 alleles by a validated test in a designated central lab prior to leukapheresis.
- •11.Participant's tumor has been pathologically reviewed by a designated central laboratory with confirmed positive NY-ESO-1 expression defined as ≥30% of cells that are 2+ or 3+ by immunohistochemistry.
- •Left ventricular ejection fraction ≥45% with no evidence of clinically significant pericardial effusion.
- •Performance status: for participants <16 years of age, Lansky >60, or for participants ≥16 and <18 years of age, Karnofsky >60, or for participants ≥18 years of age, Eastern Cooperative Oncology Group (ECOG) of 0-
- •14.Participant must have adequate organ function and blood cell counts, within 7 days prior to the day of leukapheresis procedure, as indicated in the protocol.
- •For a detailed list of Inclusion Criteria, please refer to the protocol Page No. 173-178
- •2.Participant must be ≥10 years of age at the time of signing the informed consent. Participant scheduled to receive clinical drug product supply must weigh ≥40 kg. For participant scheduled to receive intended commercial drug product supply and weighing <40kg, the Investigator must also consult with the Medical Monitor prior to inclusion.
- •3.Participant has a diagnosis of synovial sarcoma or myxoid/ round cell liposarcoma, confirmed by local histopathology and with evidence of disease-specific translocation
- •Participant has advanced (metastatic or unresectable) synovial sarcoma or myxoid/round cell liposarcoma.
- •Male or female. Contraception requirements will apply at the time of leukapheresis and treatment.
- •A representative tumor tissue specimen (archived or fresh biopsy) with associated pathology report should be available to perform NY-ESO-1 antigen expression analysis, unless a recent NY-ESO-1 expression test result from the same designated central laboratory, following the same procedures, has already been performed under a separate Adaptimmune protocol or under another substudy.
- •Leukapheresis Eligibility Screening All the Inclusion Criteria from Section 6.1.1 must apply again prior to leukapheresis. In addition, the following criteria must also apply:
- •Life expectancy ≥24 weeks
- •Participant has confirmed evidence of a relevant disease-specific translocation per below: • For synovial sarcoma, presence of a translocation involving chromosome 18 (SYT gene) and/or chromosome X (SSX1, SSX2 or SSX4 genes); • For myxoid/round cell liposarcoma, presence of a translocation involving chromosome 12 (DDIT3 gene) and/or chromosome 16 (FUS gene) and/or chromosome 22 (EWSR1 gene).
排除标准
- •1.Participant has been previously treated for advanced (metastatic or unresectable) synovial sarcoma or myxoid/round cell liposarcoma.
- •9.Participant has history of chronic or recurrent severe autoimmune or immune mediated disease (e.g. Crohn's disease, systemic lupus) requiring steroids or other immunosuppressive treatments.
- •Uncontrolled intercurrent illness including, but not limited to: a. Ongoing or active infection b. Clinically significant cardiac disease defined by congestive heart failure New York Heart Association (NYHA) Class 3 /Class 4 c. Uncontrolled clinically significant arrhythmia d. Acute coronary syndrome (angina or myocardial infarction) in last 6 months
- •Current active liver or biliary disease.
- •QTc >480 msec
- •Participant has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, fludarabine, other agents used in the study.
- •Pregnant or breastfeeding females
- •Prior/concomitant therapy: any prior treatment-related toxicities must be Common terminology criteria for adverse events <=Grade 1 at the time of initiating study intervention (except for non-clinically significant toxicities). Other lines of therapy are allowed only if guidelines and washout periods are followed.
- •Investigational treatment within 30 days or 5 half-lives (whichever is shorter) prior to leukapheresis. Investigational vaccines (other than NY-ESO-1 vaccines that are not allowed) must follow washout periods in the protocol.
- •Participant has active infection with HIV, HBV, HCV, EBV, CMV, syphilis, or HTLV as defined in the protocol
- •Has known psychiatric or substance abuse disorders that would interfere with cooperating with study requirements.
- •Central nervous system metastases.
- •Mandatory washout periods must be respected before starting lymphodepletion. In addition to confirming treatment fitness (Section 6.2.3.1), participants cannot proceed with lymphodepletion or treatment if any of the following criteria apply:
- •Participant has received cytotoxic therapy within 3 weeks prior to lymphodepleting chemotherapy.
- •Systemic corticosteroids or any other immunosuppressive therapy within 2 weeks prior to lymphodepleting chemotherapy.
- •Participant has received ≥50 Gy to a significant volume of the pelvis, long bones or spine, or a cumulative dose of radiation that, in the Investigator's opinion would predispose patients to prolonged cytopenia after lymphodepletion.
- •All of the participant's measurable lesions have been irradiated within 3 months prior to lymphodepletion.
- •23.Participant has received live vaccine within 4 weeks prior to lymphodepletion or intends to receive live vaccine during the 3 month period following administration of GSK
- •For a detailed list of Exclusion Criteria, please refer to protocol pages 178-
- •Any other prior malignancy that is not in complete remission.
- •Previous treatment with genetically engineered NY-ESO-1-specific T cells.
- •Previous NY-ESO-1 vaccine or NY-ESO-1 targeting antibody.
- •Prior gene therapy using an integrating vector.
- •Previous allogeneic hematopoietic stem cell transplant.
- •Clinically significant systemic illness: serious active infections or significant cardiac, pulmonary, hepatic or other organ dysfunction, that in the judgment of the Investigator would compromise the subject's ability to tolerate protocol therapy or significantly increase the risk of complications, or prior or active demyelinating disease.
- •Leukapheresis Eligibility Screening: Participants are not eligible if any of the exclusion criteria (section 6.2.1) apply. Please note that mandatory washout periods must be respected before starting leukapheresis. In addition, participants are not eligible if any of the following apply:
结局指标
主要结局
Overall Response Rate (ORR) per RECIST v1.1
Overall Response Rate (ORR) per RECIST v1.1
次要结局
- To evaluate efficacy of NY-ESO -1 ∙ Time to Response (TTR) ∙ Duration of Response (DoR) ∙ Disease Control Rate (DCR) ∙ Progression Free Survival (PFS)
- To evaluate safety and tolerability of NY-ESO-1 ∙ Frequency and severity of Adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI; as defined in protocol) ∙ Laboratory parameters ∙ Replication Competent Lentivirus (RCL) ∙ Instances of Insertional oncogenesis (IO)
研究者
Regulatory Affairs
Scientific
USWM Ct LLC
研究点 (8)
Loading locations...
相似试验
已完成
1 期
NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation TherapySarcomaNCT02319824Fred Hutchinson Cancer Center2
Unknown
1 期
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing MalignanciesEsophagus CarcinomaOther Metastatic Solid CancersBreast CancerLung CancerMultiple MyelomaOvarian CancerMelanomaNeuroblastomaSynovial SarcomaBladder CarcinomaNCT02457650Shenzhen Second People's Hospital36
进行中（未招募）
1/2 期
在 MET 扩增 / 过表达的晚期实体瘤中评价 MCLA-129 联合盐酸恩沙替尼治疗的 I/II 期研究CTR20254638174
招募中
1 期
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid TumorsAdvanced Solid TumorsNCT05881525TCRCure Biopharma Ltd.18
招募中
2 期
Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 InhibitorsBreast CancerNCT07258108Sun Yat-sen University35